Day: March 25, 2022

Ninepoint Partners Announces March 2022 Cash Distributions for ETF Series Securities

Written by Customer Service on March 25, 2022. Posted in Dividend Reports And Estimates.

TORONTO, March 25, 2022 (GLOBE NEWSWIRE) — Ninepoint Partners LP (“Ninepoint Partners”) today announced the March 2022 cash distributions for its ETF Series securities. The record date for the distributions is March 31, 2022 for Ninepoint High Interest Savings Fund and April 1, 2022 for Ninepoint Diversified Bond Fund, Ninepoint Alternative Credit Opportunities Fund and Ninepoint Energy Income Fund. All distributions are payable on April 8, 2022. The per-unit March distributions are detailed below:Ninepoint ETF Series Ticker Distribution per unit Notional Distribution per unit CUSIPNinepoint Diversified Bond Fund NBND $0.03230 $0.00000 65443H100Ninepoint High Interest Savings Fund NSAV $0.03027 $0.00000 65443X105Ninepoint Alternative Credit Opportunities Fund NACO $0.08894 $0.00000 65443Q100Ninepoint Energy Income...

Steering Column Control Module Market Size to Hit USD 27.26 billion by 2028 | Exhibit a CAGR of 7.5%

Written by Customer Service on March 25, 2022. Posted in Mergers And Acquisitions.

Increase in Vehicle Ownership in Developing Countries to Drive the Growth of Global Steering Column Control Module Market Pune, India, March 25, 2022 (GLOBE NEWSWIRE) — Steering Column Control Module market size is anticipated to reach USD 27.26 billion by 2028 and exhibit a CAGR of 7.5% during the forecast period. The growing electric vehicle sales and developments in autonomous driving are expected to fuel the market growth. Fortune Business Insights has presented this information in its report titled, “Steering Column Control Module Market, 2021-2028”. The market size stood at USD 15.64 billion in 2020 and USD 16.49 billion in 2021. The report provides a detailed market outline, covering each facet of definitions, classifications, applications, and industry chain frameworks. It throws light on the crucial market dynamics, together...

Victoria’s Secret & Co. Announces Acquisition of Minority Interest in Frankies Bikinis

Written by Customer Service on March 25, 2022. Posted in Mergers And Acquisitions.

REYNOLDSBURG, Ohio, March 25, 2022 (GLOBE NEWSWIRE) — Victoria’s Secret & Co. (“Victoria’s Secret” or the “Company”) (NYSE: VSCO) today announced its acquisition of a minority interest in Frankies Bikinis, LLC (“Frankies Bikinis”), a women-founded and women-led beachwear and lifestyle brand located in Venice, California. Frankies Bikinis was founded in 2012 by then 17-year-old Francesca Aiello and her mother, Mimi Aiello. The brand is widely known and recognized for its innovative, inclusive, and trend-setting aesthetic and laid-back Malibu vibe. Founder and Creative Director Francesca Aiello said, “Victoria’s Secret and Frankies Bikinis are true heritage brands in my eyes; companies that women tie unforgettable memories to, whether that be a first purchase from the brand or a memory of a time wearing it. I have such respect...

POINT Biopharma Reports Fiscal 2021 Financial Results and Provides Business Update

Written by Customer Service on March 25, 2022. Posted in Earnings Releases And Operating Results.

Reported 27-patient dosimetry data from the lead-in cohort of the SPLASH trial Randomization phase of SPLASH trial ongoing, top line data expected mid-2023 Phase 1 therapeutic trial for PNT6555, the lead of the pan-cancer PNT2004 fibroblast activation protein-alpha (FAP-alpha) inhibitor program, planned for summer 2022 Indianapolis radiopharmaceutical manufacturing facility operational and supplying doses of PNT2002 to support the SPLASH trial – view the facility online at manufacturing.pointbiopharma.com INDIANAPOLIS, March 25, 2022 (GLOBE NEWSWIRE) — POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today announced financial results for the fourth quarter and full year ended December 31, 2021 and provided...

HydroGraph Clean Power to attend CEM AlphaNorth Capital Event

Written by Customer Service on March 25, 2022. Posted in Public Companies.

VANCOUVER, British Columbia, March 25, 2022 (GLOBE NEWSWIRE) — HydroGraph Clean Power Inc. (HG.CN) (OTCMKTS:HGCPF) (the “Company” or “HydroGraph”), a commercial manufacturer of high-quality nanomaterials and alternative-energy fuels, today announced that it will conduct one-on-one meetings with investors at the CEM AlphaNorth Capital Event in Nassau, Bahamas from March 25-27, 2022. HydroGraph manufactures strategic products such as the super-material graphene used in dozens of industries, and alternative-energy fuels in high-demand such as hydrogen, all through an industry-leading patented technology that achieves the highest quality, a low cost, and, unlike conventional processes, is environmentally friendly. The technology — the Hyperion detonation system — is ideal for commercial scale: compact and modular, the small footprint...

Brompton North American Financials Dividend ETF Risk Rating Improvement

Written by Customer Service on March 25, 2022. Posted in Public Companies.

TORONTO, March 25, 2022 (GLOBE NEWSWIRE) — (TSX: BFIN, BFIN.U) Brompton North American Financials Dividend ETF (the “Fund”) announces a change to the risk rating of the Fund. The change to the Fund’s risk rating is a result of ongoing review of the risk rating and not as a result of any changes to the Fund’s investment objectives, strategies, restrictions or management of the Fund. The decrease in the risk rating was a result of decreased volatility experienced in the financials sector.Previous Risk Rating New Risk RatingMedium to High MediumAbout Brompton FundsFounded in 2000, Brompton Funds Limited (“Brompton”) is an experienced investment fund manager with income focused investment solutions including Toronto Stock Exchange listed closed-end funds and exchange-traded funds. For further information, please contact your...

Form 8.3 – [CareTech Holdings plc – 24 03 2022] – (CGWL)

Written by Customer Service on March 25, 2022. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree CARETECH HOLDINGS PLC(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e) Date position...

Novartis receives positive CHMP opinion for Jakavi® to treat acute and chronic graft-versus-host disease

Written by Customer Service on March 25, 2022. Posted in Public Companies.

CHMP opinion based on Phase III REACH2 and REACH3 trials that showed Jakavi improved response rates and failure-free survival compared to best available therapy1,2Graft-versus-host disease (GvHD) is a serious and debilitating complication of stem cell transplants, with no established standard of care for patients who do not adequately respond to first-line steroid treatment3,4Nearly half of patients experience either acute or chronic GvHD, or both, following allogeneic transplants3,4Basel, March 25, 2022 — Novartis announced today the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of Jakavi® (ruxolitinib) for the treatment of patients aged 12 years and older with acute graft versus host disease or chronic graft versus host disease...

Novartis receives positive CHMP opinion for Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma in Europe

Written by Customer Service on March 25, 2022. Posted in Public Companies.

Positive opinion paves way for third indication in Europe for Kymriah, a potentially definitive single infusion CAR-T cell therapy treatment optionCHMP opinion based on Phase II global ELARA trial demonstrating high response rates in heavily pretreated patients; 69% experienced a complete response, with an 86% overall response rate and a remarkable safety profile1If approved, Kymriah may offer an effective, new treatment option to patients with advanced follicular lymphoma to break the cycle of remittent and relapsing diseasesWell-established Kymriah safety profile and post-treatment protocols allow for flexibility to administer in the outpatient setting, reducing the burden of therapy for patients and their healthcare teams across Europe1,2 Basel, March 25, 2022 — Novartis announced today that the Committee for Medicinal Products...

Dermavant Showcases New Long-Term Durability and Tolerability Data from Phase 3 PSOARING 3 Trial of Tapinarof Cream for Adults with Plaque Psoriasis at the 2022 AAD Annual Meeting

Written by Customer Service on March 25, 2022. Posted in Public Companies.

Tapinarof demonstrated continued improvements for up to 52 weeks in efficacy outcomes, quality of life measures, and tolerability scores with no associated tachyphylaxisTapinarof was well-tolerated in sensitive skin and intertriginous areas with majority of patients experiencing no irritation for up to 52 weeks Tapinarof was well tolerated with long term use and demonstrated continued and durable improvement in quality of lifeLONG BEACH, Calif., and BASEL, Switzerland, March 25, 2022 (GLOBE NEWSWIRE) — Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today announced Phase 3 PSOARING 3 long-term extension study results demonstrating durable improvements across efficacy outcomes, quality of life measures, and tolerability...

Day: March 25, 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals